Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis is viewed positively because its orthopedics platform has repeatedly delivered MSD to HSD organic revenue growth and outperformed underlying end-markets, supported by a steady cadence of clinically meaningful new products across Recon and P&R. 2Q26 revenue of $582.8M rose 3.2% Y/Y, Recon grew 8% Y/Y and P&R was resilient with 3% organic growth, while adjusted gross margin improved about 210bps in P&R and FCF increased by $31M. The stock also appears inexpensive at less than 7x NTM EV/EBITDA, and the improving margin profile, solid 2Q26 results, and expanding product traction suggest a favorable risk/reward as integration pressures ease.

Enovis is facing a fundamentally weaker setup because slower-than-expected top-line growth, lower market growth in Prevention & Recovery, and competitive pressure in Reconstructive can drive further multiple contraction. The company also appears vulnerable to tariff exposure, a lack of new product cadence, and the risk that M&A integration fails to add meaningful growth or profitability, while its current debt position adds financial strain. Although the bone growth stimulation reimbursement headwind is estimated at only about 10% on less than 3% of sales, the broader issue is that ENOV already trades at a discount due to lower growth CAGRs and could remain capped without clearer execution.